Servier Gets Expanded FDA Approval of Tibsovo for IDH1-Mutated AML

The FDA has approved Servier Pharmaceuticals’ Tibsovo (ivosidenib) in combination with Bristol Myers Squibb’s Vidaza (IV formulation of azacitidine) to treat patients 75 years and older with newly diagnosed isocitrate dehydrogenase-1 (IDH1) mutation in acute myeloid leukemia (AML) or who have comorbidities that preclude use of intensive induction chemotherapy.

“People living with acute myeloid leukemia, especially those who are newly diagnosed and are not eligible for intensive chemotherapy, have had few treatment options,” said Susan Pandya, vice president of clinical development and head of cancer metabolism global development oncology & immuno-oncology at Servier.

Tibsovo, an IDH1 inhibitor, was first approved by the FDA in 2018. The expanded approval for IDH1-mutated AML joins the list of other approved indications, including relapsed or refractory AML and previously treated locally advanced or metastatic cholangiocarcinoma.

Click here to read the full article at FDANews

Disclaimer: BioPharma Global is not responsible for, and expressly disclaims all liability for, damages of any kind arising out of use, reference to, or reliance on any information contained within the article. Content available through the site may contain links and information to other websites. Links from BioPharma Global to third-party sites do not constitute an endorsement by BioPharma Global of the mentioned parties.

BioPharma Global is a mission-driven corporation dedicated to using our FDA and EMA regulatory expertise and knowledge of various therapeutic areas to help drug developers advance treatments for the disease communities with unmet medical needs. If you are a drug developer seeking regulatory support for Orphan Drug designation, Fast Track designation, Breakthrough Therapy designation, other FDA/EMA expedited programs, type A, B (pre-IND, EOPs), or C meeting assistance, or IND filings, the BioPharma Global team can help. Contact us today to arrange a 30-minute introductory call.

Comments are closed.